{
  "source": "PA-Notification-Opfolda.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1420-2\nProgram Prior Authorization/Notification\nMedication Opfolda™ (miglustat)\nP&T Approval Date 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nOpfolda (miglustat) is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic\nlysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe\ndisease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not\nimproving on their current enzyme replacement therapy (ERT).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Opfolda will be approved based on both of the following criteria:\na. Diagnosis of late-onset Pompe disease\n-AND-\nb. Patient has an active UnitedHealthcare medical benefit prior authorization for\nPombiliti (cipaglucosidase alfa-atga) for the treatment of late-onset Pompe disease\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Opfolda will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Opfolda plus Pombiliti\n-AND-\nb. Opfolda continues to be prescribed in combination with Pombiliti\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Opfolda [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.\n2. Pombiliti [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.\nProgram",
    "ences:\n1. Opfolda [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.\n2. Pombiliti [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.\nProgram Prior Authorization/Notification - Opfolda (miglustat)\nChange Control\nDate Change\n11/2023 New program\n11/2024 Clarified criteria without change to clinical intent. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}